Tanja Fehm

Summary

Country: Germany

Publications

  1. ncbi Selective microdochectomy after ductoscopic wire marking in women with pathological nipple discharge
    M Hahn
    Department of Obstetrics and Gynaecology, University Hospital Tuebingen, Tuebingen, Germany
    BMC Cancer 9:151. 2009
  2. ncbi Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer
    Tanja Fehm
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstrasse 7, D 72076 Tuebingen, Germany
    Breast Cancer Res 8:R60. 2006
  3. ncbi ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients
    Tanja Fehm
    Department of Obstetrics and Gynecology, University of Tuebingen, Germany
    Breast Cancer Res 10:R76. 2008
  4. ncbi Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients
    Tanja Fehm
    Department of Obstetrics and Gynecology, University of Erlangen Nuremberg, Erlangen, Germany
    Breast Cancer Res Treat 75:97-106. 2002
  5. ncbi Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies
    T Fehm
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstrasse 7, 72076 Tuebingen, Germany
    Gynecol Oncol 112:605-9. 2009
  6. ncbi Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
    Tanja Fehm
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstrasse, D 72076 Tuebingen, Germany
    Breast Cancer Res 9:R74. 2007
  7. ncbi Changes of serum HER2 status during clinical course of metastatic breast cancer patients
    T Fehm
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstrasse 7, D 72076 Tuebingen, Germany
    Anticancer Res 24:4205-10. 2004
  8. ncbi Tumor cell dormancy: implications for the biology and treatment of breast cancer
    T Fehm
    Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany
    APMIS 116:742-53. 2008
  9. ncbi Evaluation of ERalpha, PR and ERbeta isoforms in neoadjuvant treated breast cancer
    Martin Wurster
    Department of Obstetrics and Gynecology, University of Tuebingen, D 72076 Tuebingen, Germany
    Oncol Rep 24:653-9. 2010
  10. ncbi Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
    Tanja Fehm
    Department of Gynecology and Obstetrics, Calwer Strasse 7, University Hospital of Tuebingen, D 72076 Tuebingen, Germany
    Breast Cancer Res 11:R59. 2009

Collaborators

Detail Information

Publications67

  1. ncbi Selective microdochectomy after ductoscopic wire marking in women with pathological nipple discharge
    M Hahn
    Department of Obstetrics and Gynaecology, University Hospital Tuebingen, Tuebingen, Germany
    BMC Cancer 9:151. 2009
    ..To investigate the diagnostic reliability of selective microdochectomy after direct ductoscopic wire marking of suspect lesions in patients with pathological nipple discharge...
  2. ncbi Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer
    Tanja Fehm
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstrasse 7, D 72076 Tuebingen, Germany
    Breast Cancer Res 8:R60. 2006
    ..The aim of this study was to investigate the incidence of disseminated tumor cells (DTC), including apoptotic DTC, in breast cancer patients after NST, and to investigate the correlation of DTC status with therapy response...
  3. ncbi ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients
    Tanja Fehm
    Department of Obstetrics and Gynecology, University of Tuebingen, Germany
    Breast Cancer Res 10:R76. 2008
    ..Of particular interest is their oestrogen-receptor (ER) status because endocrine adjuvant therapy remains a cornerstone of breast cancer treatment...
  4. ncbi Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients
    Tanja Fehm
    Department of Obstetrics and Gynecology, University of Erlangen Nuremberg, Erlangen, Germany
    Breast Cancer Res Treat 75:97-106. 2002
    ..The serum profiles of c-erbB-2 and CA 15-3 were similar in 17 patients. In summary, our results suggest that serial determinations of serum c-erbB-2 are useful to monitor breast cancer patients...
  5. ncbi Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies
    T Fehm
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstrasse 7, 72076 Tuebingen, Germany
    Gynecol Oncol 112:605-9. 2009
    ..The aim of this study was to describe the incidence and risk factors of ONJ in patients with breast cancer or gynecological malignancies receiving bisphosphonates (BP)...
  6. ncbi Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
    Tanja Fehm
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstrasse, D 72076 Tuebingen, Germany
    Breast Cancer Res 9:R74. 2007
    ..The aim of this study was therefore to determine the HER2 status in serum and corresponding CTCs in patients with metastatic breast cancer whose primary tumors were HER2 negative or of unknown HER2 status...
  7. ncbi Changes of serum HER2 status during clinical course of metastatic breast cancer patients
    T Fehm
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstrasse 7, D 72076 Tuebingen, Germany
    Anticancer Res 24:4205-10. 2004
    ....
  8. ncbi Tumor cell dormancy: implications for the biology and treatment of breast cancer
    T Fehm
    Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany
    APMIS 116:742-53. 2008
    ..In this review, we summarize findings on different factors for tumor cell dormancy and potential therapeutic implications that should help to reduce metastatic relapse in cancer patients...
  9. ncbi Evaluation of ERalpha, PR and ERbeta isoforms in neoadjuvant treated breast cancer
    Martin Wurster
    Department of Obstetrics and Gynecology, University of Tuebingen, D 72076 Tuebingen, Germany
    Oncol Rep 24:653-9. 2010
    ..047). Results on ERalpha and PR corroborate findings of previous studies. Our data demonstrate that changes of ERbeta expression occur during PST and that total ERbeta expression and ERbeta2 may have a predictive value for PST...
  10. ncbi Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
    Tanja Fehm
    Department of Gynecology and Obstetrics, Calwer Strasse 7, University Hospital of Tuebingen, D 72076 Tuebingen, Germany
    Breast Cancer Res 11:R59. 2009
    ....
  11. ncbi Bone marrow versus sentinel lymph node involvement in breast cancer: a comparison of early hematogenous and early lymphatic tumor spread
    Andreas D Hartkopf
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwer Strasse 7, 72076 Tuebingen, Germany
    Breast Cancer Res Treat 131:501-8. 2012
    ..Conversely, a high correlation between nodal status and tumor size, histology, ER-status and lymph vessel invasion was found. Hematogenous and lymphatic tumor spread seem to be because of independent pathways of cancer progression...
  12. ncbi Hematogenous and lymphatic tumor cell dissemination may be detected in patients diagnosed with ductal carcinoma in situ of the breast
    Malgorzata Banys
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstrasse 7, 72076, Tuebingen, Germany
    Breast Cancer Res Treat 131:801-8. 2012
    ..The clinical relevance of these cells has to be further evaluated...
  13. ncbi HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor
    Natalia Krawczyk
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstrasse 7, 72076 Tuebingen, Germany
    Anticancer Res 29:4019-24. 2009
    ..The aim of this study was to assess HER2 status of persistent DTCs to determine whether the use of HER2-targeted agents might be a therapeutic option in patients with tumor cell persistence...
  14. ncbi Expression and regulation of luteinizing hormone/human chorionic gonadotropin receptors in ovarian cancer and its correlation to human chorionic gonadotropin-doxorubicin sensitivity
    Gerhard Gebauer
    Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany
    Am J Obstet Gynecol 190:1621-8; discussion 1628. 2004
    ..Ovarian cancer cell lines and tissues express gonadotropin receptors. Conjugation of cytostatics to ligands of these receptors may increase the specificity of cytotoxic drugs...
  15. ncbi Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1
    Hans Neubauer
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstrasse, Germany
    Breast Cancer Res 10:R85. 2008
    ..Breast tumors lacking the estrogen receptor-alpha (ER-alpha) have increased incidence of resistance to therapy and poorer clinical prognosis...
  16. ncbi Disseminated tumor cells in bone marrow may affect prognosis of patients with gynecologic malignancies
    Malgorzata Banys
    Department of Obstetrics and Gynecology, University of Tuebingen, University of Tuebingen, Liebermeisterstrasse 8, Tuebingen, Germany
    Int J Gynecol Cancer 19:948-52. 2009
    ..The aim of our study was to evaluate the incidence of DTC and to assess their prognostic significance in patients with gynecologic malignancies...
  17. ncbi [Detection of disseminated tumor cells in the bone marrow of breast cancer patients with a new molecular method]
    Małgorzata Banyś
    Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany
    Ginekol Pol 83:590-7. 2012
    ..Assays based on RT-PCR are available; however so far they have not been used for routine detection of DTC. Therefore, the purpose of this study was to evaluate a newly established molecular method for the detection of DTC...
  18. ncbi Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay
    Tanja Fehm
    Department of Obstetrics and Gynecology, University of Tubingen, Calwerstr 7 6, 72076, Tubingen, Germany
    BMC Cancer 12:308. 2012
    ..The purpose of this study was to compare the antitumor effect of Zol with standard chemotherapy in primary breast cancer cells using ATP-tumor chemosensitivity assay (ATP-TCA)...
  19. ncbi The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer
    Malgorzata Banys
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstrasse 7, 72076 Tuebingen, Germany
    Breast Cancer Res Treat 132:121-9. 2012
    ..Surgery does not significantly influence the tumor cell load in the blood stream. CTC phenotype before and after the surgery generally remains identical but may differ from that of the primary tumor...
  20. ncbi Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer
    Tanja Fehm
    Department of Obstetrics and Gynecology, University of Tuebingen, D 72076 Tuebingen, Germany
    Anticancer Res 24:1987-92. 2004
    ....
  21. ncbi Evaluation of a RT-PCR based routine screening tool for the detection of disseminated epithelial cells in the bone marrow of breast cancer patients
    Sven Becker
    Department of Gynaecology and Obstetrics, University Hospital Tuebingen, Calwerstrasse 7, 72076 Tuebingen, Germany
    Breast Cancer Res Treat 117:227-33. 2009
    ..Immunocytochemistry (ICC) remains the gold standard for their detection. While assays based on RT-PCR are available, they have not been used for routine detection of DTC's...
  22. ncbi Prediction of axillary lymph node status of breast cancer patients by tumorbiological factors of the primary tumor
    Tanja Fehm
    Department of Obstetrics and Gynecology, University of Tuebingen, Germany
    Strahlenther Onkol 181:580-6. 2005
    ..By including additional parameters it appears to be feasible to further improve the model in order to avoid axillary lymph node surgery in low-risk women...
  23. ncbi Symptomatic bone marrow involvement in breast cancer--clinical presentation, treatment, and prognosis: a single institution review of 22 cases
    Hans Georg Kopp
    Department of Hematology Oncology, Eberhard Karls University, Otfried Mueller Str 10, D 72076 Tuebingen, Germany
    Anticancer Res 31:4025-30. 2011
    ..The objective of this study was to provide our institution's experience with the clinical presentation, prognosis, treatment, and associated complications of marrow involvement in breast cancer...
  24. ncbi Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma
    Claudia Lengerke
    University of Tuebingen Medical Center II, Otfried Mueller Strasse 10, 72076 Tuebingen, Germany
    BMC Cancer 11:42. 2011
    ..In breast cancer, SOX2 expression was reported as a feature of basal-like tumors. In this study, we assessed SOX2 expression in 95 primary tumors of postmenopausal breast cancer patients...
  25. ncbi Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis
    Christina S Schuetz
    Department of Obstetrics and Gynecology, Microarray Facility, Department of Medical Genetics, University of Tuebingen, Tuebingen, Germany
    Cancer Res 66:5278-86. 2006
    ....
  26. ncbi Pregnancy after breast cancer: case report and review of the literature
    Barbara Lawrenz
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstrasse 7, 72076 Tuebingen, Germany
    Arch Gynecol Obstet 283:837-43. 2011
    ..The question whether to become pregnant must be discussed individually with the patient, based on tumor characteristics, stage of the disease and patient's wishes...
  27. ncbi A laminin-rich basement membrane matrix influences estrogen receptor beta expression and morphology of MDA-MB-231 breast cancer cells
    Hans Neubauer
    Department of Obstetrics and Gynaecology, University of Tuebingen, 72076 Tuebingen, Germany
    Oncol Rep 21:475-81. 2009
    ..A laminin-111-rich microenvironment seems to keep ERbeta1 at very low levels in breast cancer cells...
  28. ncbi Fertility conservation in breast cancer patients
    Barbara Lawrenz
    Department of Obstetrics and Gynaecology, University Hospital for Women, University of Tuebingen, Calwerstrasse 7, 72076 Tuebingen, Germany
    Womens Health (Lond Engl) 7:203-12. 2011
    ..Early counseling on fertility-preserving strategies is of utmost importance, so that the fertility-preserving method can be integrated into the oncologic therapy regime...
  29. ncbi Pregnancy after successful cancer treatment: what needs to be considered?
    Barbara Lawrenz
    University Women s Hospital, Tuebingen, Tuebingen, Germany
    Onkologie 35:128-32. 2012
    ..The effect is more pronounced after prepubertal radiation than for postpubertal radiation. The former cancer patient's desire to conceive can nevertheless be supported, given that pregnancy and birth are closely monitored...
  30. ncbi Clinical implications of the detection of circulating tumor cells in breast cancer patients
    Malgorzata Banys
    Department of Obstetrics and Gynecology, University of Tuebingen, Germany
    Biomark Med 6:109-18. 2012
    ..The evaluation of circulating tumor cells may become one of the crucial markers for prediction of survival and therapy monitoring, and its characterization might enable specific targeting of minimal residual, and metastatic disease...
  31. ncbi Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer
    Hans Neubauer
    Department of Obstetrics and Gynecology, University of Tuebingen, 72076 Tuebingen, Germany
    Anticancer Res 28:949-55. 2008
    ..Our purpose was to define the optimal calculation method for the adenosine triphosphate-tumor chemosensitivity assay (ATP-TCA) applied to PEOC treated with platinum-containing chemotherapy and to analyze its predictive relevance...
  32. ncbi Number of hysteroscopies and the time interval between hysteroscopy and surgery: influence on peritoneal cytology in patients with endometrial cancer
    Ingolf Juhasz-Böss
    Department of Obstetrics and Gynecology, University of Saarland, Kirrbergerstr 100, 66424 Homburg Saar, Germany
    Anticancer Res 30:2425-30. 2010
    ..As yet, no data are available showing whether the time interval between hysteroscopy and definitive surgery, or the number of preoperative hysteroscopies, have an influence on the intraperitoneal cytology results...
  33. ncbi Optimal treatment for patients with ectopic pregnancies and a history of fertility-reducing factors
    Sven Becker
    Women s University Hospital, Tubingen University, Calwerstrasse 7, Tubingen, Germany
    Arch Gynecol Obstet 283:41-5. 2011
    ..The aim of this study was to evaluate long-term reproductive outcome after salpingotomy versus salpingectomy in patients with and without additional fertility-reducing factors...
  34. ncbi Abnormal cytology during pregnancy--a retrospective analysis of patients in a dysplasia clinic
    Melanie Henes
    Tuebingen University Hospital for Women, Calwerstr 7, D 72076 Tuebingen, Germany
    Anticancer Res 33:711-5. 2013
    ..Vaginal delivery is possible in most cases...
  35. ncbi Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer
    Andreas D Hartkopf
    Department of Obstetrics and Gynaecology, University of Tuebingen, Calwer Strasse 7, 72076 Tuebingen, Germany
    Anticancer Res 31:979-84. 2011
    ..The aim of this study was to investigate whether changing CTC levels during the course of chemotherapy treatment would also be useful in monitoring response to treatment...
  36. ncbi The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells
    Hans Neubauer
    University Women s Hospital, Tuebingen, Germany
    Menopause 18:845-50. 2011
    ..The aim of this project was to investigate the influence of different estradiol (E2) concentrations and the addition of two progestogens on MCF-7 breast cancer cells overexpressing PGRMC1...
  37. ncbi Relationship between circulating tumor cells and peripheral T-cells in patients with primary breast cancer
    Ines Gruber
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwer Straße 7, 72076 Tuebingen, Germany
    Anticancer Res 33:2233-8. 2013
    ..Recent studies have found evidence for immunological influence on tumor cell dormancy. We therefore investigated the relationship between peripheral T-cells and CTCs, as immunological factors may contribute to the fate of CTCs...
  38. ncbi HER2-positive DTCs/CTCs in breast cancer
    Andreas D Hartkopf
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwer Strasse 7, 72076, Tuebingen, Germany
    Recent Results Cancer Res 195:203-15. 2012
    ..Phenotyping of CTCs/DTCs will thus help to understand mechanism of resistance to HER2-directed therapy. Moreover, patients that are likely to benefit from HER2-directed therapy despite a HER2-negative primary tumor might be identified. ..
  39. ncbi Influence of pregnancy on bone density: a risk factor for osteoporosis? Measurements of the calcaneus by ultrasonometry
    Bernhard Kraemer
    University Hospital for Women, University of Tuebingen, Calwerstr 7, 72076 Tuebingen, Germany
    Arch Gynecol Obstet 285:907-12. 2012
    ..The study aim was to investigate whether there is a significant alteration in maternal bone density during normal pregnancy...
  40. ncbi Micrometastases in axillary lymph nodes and bone marrow of lymph node-negative breast cancer patients--prognostic relevance after 10 years
    Gerhard Gebauer
    Department of Obstetrics and Gynecology, Hannover Medical School, Podbielskistrasse 380, D 30659 Hannover, Germany
    Anticancer Res 23:4319-24. 2003
    ....
  41. ncbi Fertility preservation in young female lymphoma patients: review of available options and initial experiences with their implementation in clinical routine
    Barbara Lawrenz
    University Women s Hospital, University Hospital Tuebingen, Calwerstrasse 7, Tuebingen, Germany
    Onkologie 34:88-93. 2011
    ..Available options are reviewed...
  42. ncbi A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation
    Tanja Fehm
    Department of Obstetrics and Gynecology, University of Tubingen, Tubingen, Germany
    Cancer 107:885-92. 2006
    ....
  43. ncbi Evaluation of CA125, physical and radiological findings in follow-up of ovarian cancer patients
    Tanja Fehm
    Department of Obstetrics and Gynecology, University of Tuebingen, D - 72076 Tuebingen, Germany
    Anticancer Res 25:1551-4. 2005
    ..Imaging techniques did not add clinically relevant information during follow-up and should therefore only be performed prior to surgical or therapeutical intervention...
  44. ncbi Meconium-stained amniotic fluid--perinatal outcome and obstetrical management in a low-risk suburban population
    Sven Becker
    Universitätsfrauenklinik Tübingen, Tübingen University Medical Center, Calwerstrasse 7, 72076 Tubingen, Germany
    Eur J Obstet Gynecol Reprod Biol 132:46-50. 2007
    ..To determine whether amniotic fluid (MSAF) affects obstetrical interventions and immediate perinatal outcome in a low-risk suburban population...
  45. ncbi Oncolytic virotherapy of breast cancer
    Andreas D Hartkopf
    Department of Obstetrics and Gynecology, University Clinic of Tuebingen, Tuebingen, Germany
    Gynecol Oncol 123:164-71. 2011
    ....
  46. ncbi Alterations of the RANKL pathway in blood and bone marrow samples of prostate cancer patients without bone metastases
    Tilman Todenhöfer
    Department of Urology, University Hospital Tuebingen, Tuebingen, Germany
    Prostate 73:162-8. 2013
    ..We aimed to investigate whether changes of RANKL, its inhibitor osteoprotegerin (OPG) and bone marrow-mesenchymal stromal cells (BM-MSCs) occur in PC patients without manifest bone metastases...
  47. ncbi Development of a gel-simulation model and generation of standard tables for the complete extirpation of benign breast lesions with vacuum assisted biopsy under ultrasound guidance
    Ute Krainick-Strobel
    Department of Gynaecology and Obstetrics, Breast Centre, University of Tuebingen, Tuebingen, Germany
    Ultrasound Med Biol 32:1539-44. 2006
    ..VB is suitable for the removal of benign lesions with a diameter of up to 20 mm...
  48. ncbi Cytotoxic effect of conjugates of doxorubicin and human chorionic gonadotropin (hCG) in breast cancer cells
    Gerhard Gebauer
    Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany
    Breast Cancer Res Treat 77:125-31. 2003
    ..We conclude that the cytotoxic effect of hCG-doxorubicin conjugates is mediated specifically via the hCG receptor. By using hCG conjugates, the development of more selective cytostatics can be achieved...
  49. ncbi Management of fertility preservation in young breast cancer patients in a large breast cancer centre
    B Lawrenz
    Department of Obstetrics and Gynecology, University of Tuebingen, 72076 Tubingen, Germany
    Arch Gynecol Obstet 282:547-51. 2010
    ..We present the fertility-preserving procedures performed after routine counselling for primary breast cancer patients in a large certified breast cancer centre...
  50. ncbi Oncolytic virotherapy of gynecologic malignancies
    Andreas D Hartkopf
    Department of Obstetrics and Gynaecology, University of Tuebingen, Calwer Strasse 7, 72076 Tuebingen, Germany
    Gynecol Oncol 120:302-10. 2011
    ..Here, we provide an overview of different OVs currently being used for virotherapy of gynecologic cancers and discuss challenges and implications for their future development...
  51. ncbi A pooled analysis of bone marrow micrometastasis in breast cancer
    Stephan Braun
    Department of Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
    N Engl J Med 353:793-802. 2005
    ..We assessed the prognostic significance of the presence of micrometastasis in the bone marrow at the time of diagnosis of breast cancer by means of a pooled analysis...
  52. ncbi HER-2 gene amplification can be acquired as breast cancer progresses
    Songdong Meng
    Cancer Immunobiology Center, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390, USA
    Proc Natl Acad Sci U S A 101:9393-8. 2004
    ..e., 37.5% (95% confidence interval of 18.8-59.4%). Four of the 9 patients were treated with Herceptin-containing therapy. One had a complete response and 2 had a partial response...
  53. ncbi Changes in tumour biological markers during primary systemic chemotherapy (PST)
    Hans Neubauer
    Department of Gynaecology and Obstetrics, University of Tubingen, Tubingen, Germany
    Anticancer Res 28:1797-804. 2008
    ..The influence of primary systemic therapy (PST) on the expression of relevant therapeutic markers is still under investigation...
  54. ncbi Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients
    Sven Becker
    Department of Gynecology and Obstetrics, Tubingen University Hospital, Calwerstr 7, 72076 Tubingen, Germany
    Breast Cancer Res Treat 106:239-43. 2007
    ..The aim of this study was to investigate the status of tumor cell dissemination after primary systemic therapy in relation to therapy response...
  55. ncbi Breast cancer proteomics by laser capture microdissection, sample pooling, 54-cm IPG IEF, and differential iodine radioisotope detection
    Hans Neubauer
    University Women's Hospital, , Germany
    Electrophoresis 27:1840-52. 2006
    ..This study demonstrates the potential of ProteoTope and LCM to enable extremely sensitive and precise differential analyses from well-defined primary clinical specimen...
  56. ncbi Patterns of aneusomy for three chromosomes in individual cells from breast cancer tumors
    Tanja Fehm
    Cancer Immunobiology Center, UT Southwestern Medical Center, Dallas, TX 75390-8576, USA
    Breast Cancer Res Treat 75:227-39. 2002
    ....
  57. ncbi Systemic spread is an early step in breast cancer
    Yves Hüsemann
    Department of Pathology, Division of Oncogenomics, University of Regensburg, Regensburg 93053, Germany
    Cancer Cell 13:58-68. 2008
    ..Therefore, release from dormancy of early-disseminated cancer cells may frequently account for metachronous metastasis...
  58. ncbi Circulating tumor cells in patients with breast cancer dormancy
    Songdong Meng
    Cancer Immunobiology Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390-8576, USA
    Clin Cancer Res 10:8152-62. 2004
    ..Hence, there appears to be a balance between tumor replication and cell death for as long as 22 years in dormancy candidates. We conclude that this is one mechanism underlying tumor dormancy...
  59. ncbi Her2 expression on disseminated tumor cells from bone marrow of breast cancer patients
    Sven Becker
    Tubingen University Hospital, Department of Gynecology and Obstetrics, Germany
    Anticancer Res 25:2171-5. 2005
    ..We studied the her2 expression in the BM of 105 patients with CK-positive cells present and compared it with results from the primary tumor...
  60. ncbi Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy
    Sven Becker
    Department of Gynecology and Obstetrics, University Hospital Tubingen, Tubingen, Germany
    Breast Cancer Res Treat 97:91-6. 2006
    ..020). Adjuvant treatment regimens are not able to completely eliminate cytokeratin-positive cells from the bone marrow. Prospective studies need to evaluate, whether these cells could become targets for additional adjuvant therapy...
  61. ncbi Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant
    Tanja Fehm
    Cancer Immunobiology Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Clin Cancer Res 8:2073-84. 2002
    ..The pattern of aneusomy matched a clone in the primary tumor in 10 patients. CONCLUSIONS: We conclude that the vast majority of CECs in breast, kidney, prostate, and colon cancer patients are aneusomic and derived from the primary tumor...
  62. ncbi Time is an important factor when processing samples for the detection of disseminated tumor cells in blood/bone marrow by reverse transcription-PCR
    Sven Becker
    Clin Chem 50:785-6. 2004
  63. ncbi Tumor size, axillary lymph node status and steroid receptor expression in breast cancer: prognostic relevance 5 years after surgery
    Gerhard Gebauer
    Sidney Kimmel Cancer Center, San Diego, CA, USA
    Breast Cancer Res Treat 75:167-73. 2002
    ..To summarize, prognostic factors obtained at the time of surgery can lose their significance with increasing disease-free survival...
  64. ncbi Image analysis systems for the detection of disseminated breast cancer cells on bone-marrow cytospins
    Sven Becker
    Department of Gynecology and Obstetrics, University of Tubingen, Germany
    J Clin Lab Anal 19:115-9. 2005
    ..Using ACIS, we were able to determine the bone marrow status of patients with nonmetastatic breast cancer faster, with greater accuracy, and with greater reproducibility than with the manual technique...
  65. ncbi Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer
    Pauline Wimberger
    Department of Gynecology and Obstetrics, University of Duisburg Essen, Hufelandstrasse 55, D 45122 Essen, Germany
    Gynecol Oncol 107:331-8. 2007
    ....
  66. ncbi Metabolic signature of breast cancer cell line MCF-7: profiling of modified nucleosides via LC-IT MS coupling
    Dino Bullinger
    Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, University Hospital Tubingen, Otfried Müller Str, 45, 72076 Tubingen, Germany
    BMC Biochem 8:25. 2007
    ....
  67. ncbi Proteomic expression profiling of breast cancer
    Hans Neubauer
    Universitats Frauenklinik Tubingen, Germany
    Recent Results Cancer Res 176:89-120. 2007
    ....